Please select the option that best describes you:
When do you evaluate patients with Parkinson's disease and cognitive decline for concurrent Alzheimer's disease?
Are such patients candidates for anti-amyloid therapy?
Answer from: at Academic Institution
Parkinson’s disease (PD) often includes Alzheimer’s disease (AD) “co-pathology” in up to 80% of cases. This challenges the notion that PD is a synucleinopathy; it affects many proteins beyond α-synuclein. Thus, cognitive decline in PD may be associated with AD pathology...
Sign in or Register to read more